Abbonarsi

Long term outcomes after repeat lymph node dissections for persistent or recurrent differentiated thyroid cancer - 13/12/24

Doi : 10.1016/j.amjsurg.2024.116045 
Martin Jose Barrio a, Nikita Pozdeyev b, c, Robert C. McIntyre a, Maria B. Albuja-Cruz a, Bryan R. Haugen b, Christopher D. Raeburn a,
a Division of GI, Trauma, and Endocrine Surgery, Department of Surgery, University of Colorado School of Medicine, 12631 E 17th Ave., C-313 Mail Stop, Aurora, CO, 80045, United States 
b Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, 12801 E. 17th Ave., 7103, Research 1 South, Aurora, CO, 80045, United States 
c Department of Biomedical Informatics, University of Colorado School of Medicine, 1890 N. Revere Court, Mailstop F600, Aurora, CO, 80045, United States 

Corresponding author. Department of Surgery, University of Colorado School of Medicine 12631 East 17th Avenue, Room: 6111, Aurora, CO, 80045, United States.Department of SurgeryUniversity of Colorado School of Medicine12631 East 17th AvenueRoom: 6111AuroraCO80045United States

Abstract

Background

The primary treatment for locoregional recurrent/persistent differentiated thyroid cancer (DTC) is repeated lymph node dissection; however, there are limited reports on the safety and long-term efficacy of multiple operations.

Methods

Patients who underwent a cervical lymph node dissection between 1998 and 2022 were included in this study. Demographics, initial thyroid surgery, subsequent lymph node dissections, follow up information, and response to therapy were acquired.

Results

After one, two, three and four re-operations, 112/314 (35.7 ​%), 16/79 (20.3 ​%), 3/25 (12 ​%), and 0/3 (0 ​%) patients (p ​< ​0.001) had an excellent response, respectively, resulting in a cumulative rate of 41.7 ​% (131/314). The risk for permanent hypoparathyroidism (2.9 ​%) or recurrent laryngeal nerve injury (2.2 ​%) was 5.1 ​% (14/272). This was higher in patients undergoing re-operative central neck dissection (CNDx) (8.7 ​%, 10/114) versus those who did not undergo a previous CNDx (2.5 ​%, 4/158, p ​< ​0.02).

Conclusions

Surgery remains the primary treatment for recurrent/persistent DTC, however, the likelihood of an excellent response decreases with additional operations. The risk of permanent complications is low but is more likely to occur during redo CNDx.

Il testo completo di questo articolo è disponibile in PDF.

Highlights

The likelihood of an excellent response for thyroid cancer decreases with each additional cervical lymph node operation.
The overall risk for permanent hypoparathyroidism (2.9 ​%) or recurrent laryngeal nerve injury (2.2 ​%) was 5.1 ​%.
The risk of these complications was higher in patients undergoing re-operative central neck dissection.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Thyroid cancer, Neck dissection, Response to therapy


Mappa


© 2024  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 239

Articolo 116045- gennaio 2025 Ritorno al numero
Articolo precedente Articolo precedente
  • Healthcare disparities in access to surgical management and outcomes of patients with nonmetastatic primary liver cancer: A population based study from Louisiana tumor registry
  • McKenzie Hargis, Aimée Galatas, Denise Danos, Hannah R. Malinosky, Sydney McManus, Kevin Sullivan, Mohammad Al Efishat, John Lyons, James C. Watson, Mary Maluccio, Omeed Moaven
| Articolo seguente Articolo seguente
  • Examining the false-negative rate of a negative axillary node ultrasound-guided core needle biopsy in breast cancer patients undergoing upfront surgery
  • Christine Rogers, Sarah Zeien, Kaleen Puccetti, Julie M. Jorns, Amanda L. Kong, Solomon Cherian, Chandler S. Cortina

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.